Skip to main content
. 2021 Sep 3;18(10):2344–2357. doi: 10.1038/s41423-021-00760-2

Fig. 7.

Fig. 7

Schematic illustration of the EcNL4 therapeutic. Briefly, EcNL4 was orally administered, colonized the colitis sites, ameliorated colitis by upregulating SCFA concentrations, decreasing inflammation and enriching probiotics such as Akkermansia spp. Figure captions are exhibited above the figure